Stephen Burbidge, who holds a PhD in molecular genetics, is to lead research and discovery at Rewind Therapeutics SA, a developer of therapeutics directed at promoting remyelination in the central nervous system. Dr Burbidge joins from 3D Consultants, a UK advisory company focused on drug discovery and development. Previously, he led discovery and preclinical projects at Proximagen Ltd. Based in Belgium, Rewind is targeting diseases such as multiple sclerosis and nerve injuries.
Rewind Therapeutics announced the appointment on 29 November 2022.
Copyright 2022 Evernow Publishing Ltd